Skip to main content
Premium Trial:

Request an Annual Quote

Accelerate Dx Q1 Revenues Slide 13 Percent

NEW YORK (GenomeWeb) – Accelerate Diagnostics' first quarter revenues dropped 13 percent year over year, the company said in a regulatory document on Friday.

In a Form 10-Q filed with the US Securities and Exchange Commission, the Tucson, Ariz.-based firm reported revenues of $14,000 for the three months ended March 31, compared to $16,000 in the year-ago quarter. Revenues for both quarters derived from licensing and royalty revenues.

The drop resulted from fluctuations in partner sales volumes, which affected Accelerate, it said in its SEC document.

Its net loss for the first quarter rose to $5.2 million, or $.12 per share, from a net loss of $2.5 million, or $.09 per share, a year ago. The company increased its R&D spending year over year to $3.6 million from $1.9 million as its number of employees and the purchases of laboratory and instrument engineering supplies rose, Accelerate said. SG&A costs increased to $2.0 million from $629,000, driven by salaries and other expenses as the company ramped up its operations, it added.

Accelerate exited the first quarter with $26.1 million in cash and cash equivalents. Last week, it said that it raised $45.0 million in a rights offering.

The firm is developing instruments for the rapid identification and antibiotic-susceptibility testing of infectious pathogens. Its ID/AST instrument uses a proprietary culture-free process for genomic and phenotypic detection technologies that reduces time to result while maintaining high sensitivity and specificity, it said.

The Scan

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.

Study Looks at Parent Uncertainties After Children's Severe Combined Immunodeficiency Diagnoses

A qualitative study in EJHG looks at personal, practical, scientific, and existential uncertainties in parents as their children go through SCID diagnoses, treatment, and post-treatment stages.

Antimicrobial Resistance Study Highlights Key Protein Domains

By screening diverse versions of an outer membrane porin protein in Vibrio cholerae, researchers in PLOS Genetics flagged protein domain regions influencing antimicrobial resistance.

Latent HIV Found in White Blood Cells of Individuals on Long-Term Treatments

Researchers in Nature Microbiology find HIV genetic material in monocyte white blood cells and in macrophages that differentiated from them in individuals on HIV-suppressive treatment.